National utilization of reverse total shoulder arthroplasty in the United States.
William W Schairer, Benedict U Nwachukwu, Stephen Lyman...
https://pubmed.ncbi.nlm.nih.gov/25440519/Actively Recruiting
Led by Nickolas Garbis · Updated on 2025-03-07
110
Participants Needed
1
Research Sites
52 weeks
Total Duration
This research aims to evaluate whether prophylactic conjoint tendon lengthening CTL during reverse shoulder arthroplasty RSA can prevent or reduce anterior shoulder pain one year after surgery. RSA is a surgical treatment for severe shoulder arthritis with rotator cuff damage that reverses the ball and socket of the shoulder joint to improve function and pain. Some patients experience persistent front shoulder pain after RSA, possibly due to increased tension on the conjoint tendon, and this study will investigate if CTL can address this issue. Participants will be randomly assigned to one of two groups one receiving standard RSA and the other receiving RSA combined with CTL, where the conjoint tendon is incised and lengthened during surgery to reduce tension. The study will compare outcomes at 6 and 12 months after surgery between these groups, assessing pain intensity, shoulder motion, strength, activity levels, and patient-reported results. The trial will also explore factors that may predict how well patients respond to CTL. During the study, participants will undergo regular assessments including the American Society of Shoulder and Elbow Surgeons ASES score at 12 months as the primary outcome. Secondary measures include the Visual Analog Scale VAS for pain and the Shoulder Pain and Disability Index SPADI. Participants will be monitored through these evaluations to understand the impact of the surgical procedures on their shoulder pain and function over the course of one year.
CONDITIONS
Prophylactic Conjoint Tendon Lengthening During Reverse Shoulder Arthroplasty Outcomes
N
Nickolas G Garbis, MD
D
Dane H Salazar, MD, MBA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nickolas Garbis
Lead Sponsor
Loyola University School of Medicine
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Prophylactic Conjoint Tendon Lengthening | Standard Reverse Shoulder Arthroplasty |
|---|---|---|
| What it is | Surgical procedure where, during primary reverse shoulder arthroplasty, the conjoint tendon is lengthened prophylactically to potentially reduce anterior shoulder pain. | The standard surgical approach for reverse shoulder arthroplasty without routine lengthening of the conjoint tendon. |
| Role in this trial | Evaluated as the investigational procedure to see if prophylactic tendon lengthening improves outcomes in reverse shoulder arthroplasty. | Serves as the active comparator and reflects usual clinical practice for primary reverse shoulder arthroplasty. |
| Primary use | Investigational adjunct to surgery intended to reduce or prevent anterior shoulder pain after reverse shoulder arthroplasty. | Established procedure for the surgical management of shoulder osteoarthritis, especially in settings of rotator cuff deficiency or complex reconstruction. |
| How it is given or performed | Following surgical preparation for reverse shoulder arthroplasty, the conjoint tendon is surgically incised and lengthened during the procedure. | Standard surgical procedure for reverse shoulder arthroplasty without additional tendon lengthening. |
| Evidence status | Limited published evidence for prophylactic use; existing reports focus on tendon release for persistent or recalcitrant pain after surgery, not initial prevention. | Supported by extensive published experience and accepted as standard of care for surgical management of glenohumeral osteoarthritis and rotator cuff deficiency. |
| Important limitations | Unknown whether prophylactic lengthening reduces postoperative pain or functional complications. No randomized controlled data demonstrate preventive benefit, and over-lengthening could potentially affect shoulder biomechanics. | Some patients experience persistent or recurrent anterior shoulder pain postoperatively; may require additional procedures, including possible conjoint tendon release. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day to several days
Participants undergo reverse shoulder arthroplasty surgery, with or without prophylactic conjoint tendon lengthening, followed by immediate recovery in the hospital.
1 surgical visit and immediate post-operative hospital stay
Duration - 12 months
Participants are monitored for recovery, pain levels, shoulder function, and any complications following surgery.
Visits at 6 months and 12 months post-surgery
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William W Schairer, Benedict U Nwachukwu, Stephen Lyman...
https://pubmed.ncbi.nlm.nih.gov/25440519/Neeraj Vij, Sailesh Tummala, Eahsan Shahriary...
https://pubmed.ncbi.nlm.nih.gov/38725735/Robert Z Tashjian, Jeffrey J Frandsen, Garrett V Christensen...
https://pubmed.ncbi.nlm.nih.gov/33345243/Gregory V Gomez, G Russell Huffman
https://pubmed.ncbi.nlm.nih.gov/37587959/Daniel G Schwartz, Sang Hoon Kang, T Sean Lynch...
https://pubmed.ncbi.nlm.nih.gov/22608931/Eric M Black, Susanne M Roberts, Elana Siegel...
https://pubmed.ncbi.nlm.nih.gov/26163279/Gregory N Drake, Daniel P O'Connor, T Bradley Edwards
https://pubmed.ncbi.nlm.nih.gov/20049573/Pascal Boileau, Barbara Melis, David Duperron...
https://pubmed.ncbi.nlm.nih.gov/23706884/Oke A Anakwenze, Vamsi K Kancherla, Gregory F Carolan...
https://pubmed.ncbi.nlm.nih.gov/26566565/Paul M Grammont, Emmanuel Baulot
https://pubmed.ncbi.nlm.nih.gov/21732025/Nickolas Garbis
Lead Sponsor
Loyola University School of Medicine
Collaborating Sponsor